INmune Bio

Tokyo, August 26, 2026 Daiichi Sankyo announced that the first patient has been dosed in TROPION-Urothelial04, a global Phase...

BOCA RATON, Fla., Aug. 26, 2026 INmune Bio Inc. has advanced Ebstrocel™ toward potential European commercialization after submitting two...

BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...

BOCA RATON, Fla. | July 20, 2026 INmune Bio Inc. announced the successful completion of a major commercial manufacturing...

BOCA RATON, Fla., July 15, 2026 INmune Bio announced the publication of a peer-reviewed preclinical study in the Journal...

INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...

BOCA RATON, Fla., May 15, 2026 INmune Bio announced the publication of positive Phase 2 MINDFuL trial results for...